Monoclonal antibody BIS-1

Drug Profile

Monoclonal antibody BIS-1

Latest Information Update: 03 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University HealthSystem Consortium Services Corporation; University Hospital Groningen
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Epithelial cell adhesion molecule inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant ascites; Pleural effusion; Renal cancer

Most Recent Events

  • 05 Sep 2001 A preclinical study has been added to the Cancer pharmacodynamics section
  • 16 Jul 1998 Profile reviewed
  • 16 Dec 1997 Phase-I clinical trials for Malignant ascites in Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top